Dulaglutide
Also known as: Trulicity, Dulaglutida
Overview
Long-acting GLP-1 receptor agonist composed of a GLP-1 analog fused to a modified IgG4 immunoglobulin Fc fragment. This fusion protein confers an extended half-life of approximately 5 days, enabling weekly administration. Approved for type 2 diabetes treatment and cardiovascular risk reduction in diabetic patients.
FDA-approved as Trulicity (2014) for type 2 diabetes treatment, including cardiovascular risk reduction in diabetic patients, demonstrated in the REWIND study.
Fusion protein (~59.7 kDa) — GLP-1 analog fused with IgG4 Fc fragment
Half-life
~5 days
Administration Route
Subcutaneous
Category
Metabolic & Fat Loss
Mechanism of Action
- GLP-1 receptor agonism with glucose-dependent insulin secretion stimulation
- Suppression of glucagon secretion in hyperglycemic states
- Delayed gastric emptying
- Appetite and caloric intake reduction via hypothalamic signaling
- Improved insulin sensitivity in peripheral tissues
- Cardiovascular protection with reduction of major adverse cardiovascular events (MACE)
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 0.75-4.5 mg per week (subcutaneous) |
| Frequency | Once weekly |
| Timing | Same day of the week, any time of day, regardless of meals |
| Duration | Continuous use (with gradual dose escalation) |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Nausea
- Diarrhea
- Vomiting
- Abdominal pain
- Decreased appetite
- Fatigue
Presentations & Preparation
Vials of Dulaglutide found in the research market:
Reconstitution
- Diluent: Not applicable — pre-filled pen ready for use
- Volume: Single-dose pre-filled pen (0.5 ml)
- Use single-dose pre-filled pen — no reconstitution required
- Inject subcutaneously in abdomen, thigh or arm, rotating sites
- Dose escalation every 4 weeks (0.75 → 1.5 → 3.0 → 4.5 mg)
- Each pen is single-use — discard after administration
Storage
- Lyophilized: Not applicable — ready-to-use solution
- Reconstituted: Refrigerated 2-8°C (unopened); room temperature up to 14 days (maximum 30°C)
- Do not freeze — discard if frozen
- Protect from direct light
- Keep in original packaging until time of use
Scientific Studies
Published studies on Dulaglutide.
Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes (AWARD-1)
Wysham C, Blevins T, Arakaki R, Colon G, Garcia P, Atisso C, et al.
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al.
Related Peptides
5-Amino-1MQ
50 mg per capsule · 1-2 times daily
Adipotide
0.5-1 mg/kg per injection (subcutaneous) · Once daily
AICAR
50-150 mg per injection · 2-3 times per week
AOD 9604
300-600 mcg per injection · Once daily
Cagrilintide
1.2-4.5 mg per week (subcutaneous) · Once weekly
Exenatide
5-10 mcg per injection (subcutaneous) · Twice daily (Byetta) or once weekly (Bydureon)